Literature DB >> 31808395

High mortality rates after radical cystectomy: we must have acceptable protocols and consider the rationale of cutaneous ureterostomy for high-risk patients.

Fernando Korkes1, Juan Palou2.   

Abstract

Entities:  

Year:  2019        PMID： 31808395     DOI： 10.1590/S1677-5538.IBJU.2019.05.03

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN： 1677-5538            Impact factor:   1.541


× No keyword cloud information.
  5 in total

1.  Mortality after radical cystectomy is strongly related to the institution's volume of surgeries.

Authors:  Fernando Korkes; Frederico Timóteo Silva Cunha; Matheus Prado Nascimento; Antonio Flávio Silva Rodrigues; Willy Baccaglini; Sidney Glina
Journal:  Einstein (Sao Paulo)       Date:  2020-12-07

2.  Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy.

Authors:  Shang Huang; Hanzhong Chen; Teng Li; Xiaoyong Pu; Jiumin Liu; Xuecheng Bi
Journal:  BMC Geriatr       Date:  2021-01-13       Impact factor: 3.921

3.  Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies.

Authors:  Fernando Korkes; Fernando Maluf
Journal:  Int Braz J Urol       Date:  2021 Mar-Apr       Impact factor: 1.541

4.  Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project.

Authors:  Fernando Korkes; Frederico Timóteo; Suelen Martins; Matheus Nascimento; Camila Monteiro; José H Santiago; Willy Baccaglini; Marcel A Silveira; Eduardo F Pedroso; Marcello M Gava; Prashant Patel; Phillipe E Spiess; Sidney Glina
Journal:  JCO Glob Oncol       Date:  2021-09

Review 5.  Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review.

Authors:  Fernando Korkes; Eduardo Fernandes; Felipe Arakaki Gushiken; Felipe Placco Araujo Glina; Willy Baccaglini; Frederico Timóteo; Sidney Glina
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.